Developing new medicines is a multi-stage process that brings together scientific research, clinical testing and regulatory assessment. Each stage helps researchers build a clearer understanding of a potential treatment, assess its safety and determine whether it can provide benefits to patients.
The process begins with laboratory research, where scientists identify potential treatment targets and develop compounds for further investigation. Promising candidates then undergo preclinical testing to assess their safety and suitability for human trials.
Clinical development follows, with three main phases designed to evaluate different aspects of a potential medicine. Early trials focus on safety and dosage, followed by studies involving patients to assess effectiveness and identify possible side effects.
Larger Phase 3 trials provide further evidence by testing treatments across broader patient groups. These studies help establish how well a medicine works, assess its safety and compare its performance with existing treatments or placebos.
The results are then submitted to regulators such as the US Food and Drug Administration (FDA) for review. Approval allows a medicine to progress towards commercial availability, subject to the regulator being satisfied with the evidence provided.
Although drug development requires considerable time, investment and research, each stage contributes to the advancement of medical science. Continued progress through the development process supports the introduction of new treatment options and the potential to address unmet medical needs.
Biotech Growth Trust plc (LON:BIOG) seeks capital appreciation through investment in the worldwide biotechnology industry. The Company and the Company’s Portfolio Manager believe that there is a high congruence between companies that seek to act responsibly and those that succeed in building long-term shareholder value.
